

**Evgeny Belov** 

# A New Ultrasound Non-Invasive Surgery Platform – SonoFusion








contact@sono-fusion.com



www.sono-fusion.com



Israel, Bar Yehuda Road 44, Nesher



## Approximately 40% of people worldwide will face one of these major conditions in their lifetime:

- ▶ Oncology: Liver, breast, and prostate cancers.
- Women's Health: Uterine fibroids.
- ▶ Bone Metastases: Pain and complications associated with advanced cancer.
- ▶ Heart Issues: Arrhythmias requiring cardiac tissue ablation.
- ▶ Urological Problems: Benign prostatic hyperplasia (BPH) and prostate cancer.
- ▶ Gynecological Disorders: Endometriosis and adenomyosis.

## Many of patients with these conditions may not be suitable for surgery:

- ► Non-operable tumors
- ► Hard-to-Reach Areas
- ► Post-Treatment Recovery
- ► High surgical costs
- Unavailable surgical facilities



# **Our Vision**

Our mission is to revolutionize healthcare by replacing invasive surgeries with effective, non-invasive surgery platform with real time ultrasound imaging feedback. We aim to deliver treatments that are accessible to more patients, enable faster recovery, and are affordable for everyone. By providing a lowcost system for every physician's clinic, we strive to make advanced care universally available.

## \*Over 70% Cost Savings


### **Our Advantages:**

Non-invasive treatment procedure.

Simple and ultra-fast - no complex preparations needed

More effective and safe.

Outpatient treatment - no hospitalization required.



## **Our Impact:**

PATIENTS - Outcomes and quality of life PROVIDERS – Simple and safe treatment PAYERS – majored cost of care reducing\*



# **Our Solution**

Is an innovative ultrasound treatment platform that combines histotripsy and thermal ablation to deliver precise, non-invasive ultrasound procedure.

Robot and navigation algorithm



- Compact & cost optimized phased array + robotic arm (3D + angle positioning)
- High flexibility, minimal space
- Fits any geometry with minimal space

Transducer and electronics



- In-house design
- Cost optimized solution
- Direct skin-coupling
- Continuous and pulse mode(Histotripsy or Thermal ablation or combination)

Ultrasound Imaging feedback



- Real-time imaging feedback
- Full treatment navigation control

SonoFusion









# **Our Solution**

A non-invasive and effective surgical platform that combines **Histotripsy and Thermal Ablation Ultrasound**. It allows us to focus at depths of 0-10 cm with an 8kW peak and 1kW continuously(acoustic).

## Histotripsy

Ultra-high amplitude, microsecond-duration sound pulses are directed at the targeted tissue.

The rapid expansion and collapse of microbubbles cause destruction of the tissue at a sub-cellular level

Direct acoustical feedback

#### Thermal

High-amplitude, continuous sound energy is directed at the targeted tissue

Temperature rise destroys targeted tissue

No bleeding or other side effects occur

HIFU

### Combined

Ultra-fast, non-invasive treatment

Easy procedure setup

Safe, reduces risks, and ensures faster recovery time.

No MRI required – usable in small clinics

Affordable, reliable, cost optimized design

SonoFusion




Histosonics





## **Transducer and System View**









Experts at in-house development of advanced transducers

## **Live Performance Showcase**



Stability

Line lesion








**Pattern lesion** 

Experts in achieving real outcomes.

# **Ultrasound Feedback**

### **Electronically steered ablation**





#### Precise focal ablation





# **Main Competitors**

Feature	SonoFusion	HistoSonics	Haifu	
Technology	Histotripsy + Thermal	Histotripsy	Thermal	
Navigation	Imaging US	Imaging US	Imaging US	
Feedback	Ultrasound real time	Ultrasound real time	Ultrasound Post treatment	
Accuracy	1mm	1mm	1mm	
Volume	0-200cc (no bleeding)	0-1.6cc	0-200cc (no bleeding)	
Setup	Direct skin-coupling	Water bath setup	Water bath setup	
Transducer design	In-house	Outsourced	In-house	
Application	Liver, breast, BPH, prostate, uterine fibroids	Liver (FDA approved)	Liver, kidney, pancreas, breast, uterine fibroids-no FDA aproval	
Treatment mode	Continuous and pulse mode	Pulse mode	Continuous mode	
Treatment time	Fast	Slow	Slow	
Depth	~100mm(can be adapter to 200mm)	~100mm	~100mm	

## SonoFusion Estimated Procedure Cost & Time

Indication	Setting	Time of Procedure	SonoFusion Estimated Cost	Midpoint
Liver Cancer	Inpatient	90–120 min	\$3,200-4,200	\$3,700
Uterine Fibroids	Outpatient	45–60 min	\$1,300-1,800	\$1,550
Breast Cancer	Outpatient	45-60 min	\$1,800-2,300	\$2,050
Prostate Cancer	Outpatient	60-90 min	\$1,800-2,300	\$2,050
Bone Metastases	Outpatient	45–60 min	\$1,800-2,300	\$2,050
Arrhythmias	Inpatient	120-150 min	\$3,200-4,200	\$3,700
ВРН	Outpatient	30–45 min	\$1,300-1,800	\$1,550
Adenomyosis	Outpatient	45–60 min	\$1,800-2,300	\$2,050

# Procedure Price Estimation calculation example

Liver Cancer Staff: \$2,000

• Disposables: \$300

• Facility: \$2,000

• Amortization: \$80

 $$4,380 \rightarrow rounded$ \$3,200-4,200

## Standard Procedures cost vs SonoFusion

Indication	Standard Procedure Avg Cost	SonoFusion Avg Cost	Δ Savings (USD)	SonoFusion Cost 20% uplift (USD)	Savings %	Savings (USD)
Liver Cancer	\$31,989	\$3,700	\$28,289	\$9,358	<mark>70.7%</mark>	<mark>\$22,631</mark>
Uterine Fibroids	\$15,155	\$1,55O	\$13,605	\$4,471	<mark>70.5%</mark>	<mark>\$10,684</mark>
<b>Breast Cancer</b>	\$40,225	\$2,050	\$38,175	\$9,685	75.9%	\$30,540
Prostate Cancer	\$22,625	\$2,050	\$20,575	\$6,165	72.8%	\$16,460
Bone Metastases	\$15,65O	\$2,050	\$13,600	\$4,770	69.5%	\$10,880
Arrhythmias	\$27,650	\$3,700	\$23,950	\$8,490	69.3%	\$19,160
BPH	\$8,070	\$1,550	\$6,520	\$2,854	64.6%	\$5,216
Adenomyosis	\$17,035	\$2,050	\$14,985	\$5,047	70.4%	\$11,988

# **Market Opportunity**



#### **Liver Cancer:**

Market Size: \$3.8 billion

Growth: CAGR 11.5% (2025-2034)

Key Focus: Non-invasive tumor ablation for liver.



#### Women's Health (Uterine Fibroids):

Market Size: **\$5.3 billion** 

Growth: CAGR 9% (2024-2032)

Key Focus: Non-surgical treatment for uterine fibroids.



#### Cardiology:

Market Size: \$2.8 billion

Growth: CAGR 9.22% (2025-2034)

Key Focus: Cardiac tissue ablation for arrhythmias.



#### Oncology:

Market Size: \$21.8 billion

Growth: CAGR 11.5% (2025-2034)

Key Focus: Non-invasive tumor ablation for liver, breast and prostate.



#### **Urology (Benign Prostatic Hyperplasia):**

Market Size: \$1.6 billion

Growth: CAGR 5.6% (2024-2030)

Key Focus: Minimally invasive treatments for BPH.



#### **Bone Metastasis:**

Market Size: **\$3.1 billion** 

Growth: CAGR 8.1% (2023-2031)

Key Focus: Pain relief for cancer patients.



#### **Gynecology (Adenomyosis):**

Market Size: **\$2 billion** 

Growth: CAGR 6% (2025-2034)

Key Focus: Non-invasive treatment for adenomyosis.



#### **SUM: Market Opportunity:**

Total Market Size: \$36.8 billion


Average CAGR: 10.9%



# **Market Opportunity**

### **Global Market**

- Oncology
- Bone Metastasis
- Cardiology
- Urology
- Gynecology
- Women's Health



### Roadmap

#### Initial:

- ▶ Uterine fibroids
- ► Liver cancer
- ► Thyroid cancer
- ► Breast cancer
- ► Endometriosis and adenomyosis
- Pain relief for cancer patient:

#### Mid-term:

- ► Minimally invasive treatments for BPH
- Prostate cancer

#### Long-term:

 Cardiac tissue ablation for arrhythmias.

# Regulatory Strategy – FDA 510(k)

#### **Predicate Devices:**

- Insightec MRgFUS FDA approved
- Philips MR-HIFU FDA approved
- Profound Medical Sonalleve FDA approved
- HistoSonics FDA approved

#### Competitors

- Insightec MRgFUS
- Philips MR-HIFU
- Haifu JC200
- Alpinion Alpius 900
- Profound Medical Sonalleve Theraclion Sonovien
- HistoSonics



# Business Model Opportunity

Total U.S potential market size:\$36.8B

Total U.S. Potential: 12,000-17,000 installations.

## **Company Objectives**



#### 2-year milestones:

- ► Series A to found
- ► Full Integration
- Animal clinical trials

- ► Regulatory strategy preparation FDA/MDR
- ► Patents submission
- ► Human trials preparation



# **Patents**

#### Will be submitted



Method for Assembling an Ultrasound Transducer with Optimized Material Combinations



Pressure-Compensated Closed-Loop Cooling Water System



Method for Direct High-Power Ultrasound Coupling to the Body Surface



Multi-Mode Ultrasound Driver Electronics for Histotripsy and Continuous-Wave Operation



## Submitted patents (provisional)

Combined Histotripsy and Thermal Ablation Method Using High Intensity Focused Ultrasound (HIFU) with Cavitation– Guided Feedback - 63/807,927



Robotic Volumetric Ultrasound Treatment with Z-Steered Beam, X-Y Gantry Motion, and Transducer Articulation



Method for Direct Acoustic Feedback of a Cavitation Cloud via Phase Correlation Analysis



Apparatus for Digital Beam Steering in a Switching-Mode Ultrasound Driver



# 3-year Milestones Plan

2024

Research

Development Transducer

Development HW

Development SW

Platform Integration

Lab Validation - POC

System integration

Working prototype

2025

Series A to found

WE ARE HERE

2025

Integration visualization

Integration Robotic arm

Platform preparation for clinical trials

Regulatory strategy preparation

Patents submission

Histology Research

2025-Q4

Platform preparation for clinical trials

Animal clinical trials preparation

Regulatory strategy preparation

2026-Q1-Q2

Animal clinical trials (part of FDA submission)

Human trials system ready (part of FDA submission) 2026 Q3-Q4

FIH clinical trials (part of FDA submission)



# The Team

The team successfully founded previous products



## Evgeny Belov, B.Sc.

- 16 years of medical device industry experience and commercial leadership.
- Sofwave, Syneron-Candela, Iluminage, Neuronix, Chronisense, Arineta, Horizon 2020



## Oleg Prus, PhD.

- 20 years of experience in high-power focused ultrasound (HIFU) transducer technology, ultrasound technology development, algorithmics, simulations.
- Insightec





# Contact Detail



Evgeny Belov



+972-48339231



Israel, Bar Yehuda Road 44, Nesher



www.sono-fusion.com



evgenyb@sono-fusion.com